These alterations, including oncogenic mutations in PIK3CA and IDH2, have already been categorized as Level 1 alterations in other cancer types, but are still emerging as potential therapeutic targets in NSCLC (Scheffler et al., 2014; Rodriguez et al., 2020). This evidence concerns the gene IDH2 and cancer.